World Sepsis Day: A race against time
Every 2.8 seconds, someone dies from sepsis. Commonly known as “blood poisoning”, sepsis is a leading cause of deaths from bacterial infections, threatening the lives of up to 50 million people every year.
Sepsis is a life-threatening condition that demands our immediate attention. Despite better chances of recovery and survival with early detection and treatments, there is no guarantee of a favourable outcome. Antibiotic-resistant germs can significantly complicate treatment, hence the need for a multi-disciplinary approach to understand, prevent, and treat sepsis effectively. The emphasis must be on infection prevention.
Ecraid CEO Marc Bonten says, “Sepsis is a critical health threat that demands our immediate attention. I am proud to say that, since the formation of Ecraid in 2022, most of our projects and studies address the challenges posed by sepsis and other infectious diseases.”
Advancing sepsis research: Ecraid’s collaborative approach
Ecraid’s current portfolio includes PNEUMO, which is managed by its operations team, REMAP-CAP, the EU-funded ECRAID-Base Perpetual Observation Studies, SNAP, NeoDeco and RECOVERY.
Ecraid's vaccination team is also involved in the global E.mbrace study, a close collaboration with UMC Utrecht to investigate a potential new vaccine against conditions such as sepsis caused by the Escherichia coli (E. coli) bacteria, often stemming from urinary tract infections (UTIs). The vaccination team is recruiting patients above 60 years old, who have been treated for UTI in the past two years and have one or more other risk factors for bloodstream infections.
“On World Sepsis Day, I want to highlight Ecraid’s ongoing activities and growing collaborations with our academic partners and extensive ‘warm-base’ network of hospitals, laboratories and primary care sites focused on infectious diseases across Europe and beyond. Thank you to everyone involved in making our progress possible. Our mission is to join forces to collaborate and efficiently deliver high-impact studies. Together, we can strive to reduce the impact of infectious diseases on individual and population health.”
– Ecraid CEO, Marc Bonten